Abstract-The effects of chronic treatment with imipramine, a tricyclic antidepres sant, or lithium, an antimanic-depressive illness drug, on postsynaptic serotonin-1A (5-HT1A) and 5-HT1B sites and on presynaptic 5-HT3 sites in the frontal cortex and hippocampus from rat brains were studied. Chronic i.p. administration (21 days) of imipramine reduced the maximum number of binding sites (Bmax) for postsynaptic 5-HT1A as monitored by the radioligands 3H-5-HT or 3H-8-hydroxy-2-(di-npropylamino)tetralin (3H-8-OH-DPAT), but did not change the Bmax for postsynaptic 5-HT1B and presynaptic 5-HT3 in either the frontal cortex or the hippocampus. Chronic i.p. administration (21 days) of lithium reduced the Bmax for postsynaptic 5-HT1A sites in the hippocampus, but not in the frontal cortex. There was a specific difference between imipramine and lithium regarding the inhibitory effect on postsynaptic 5-HT1A sites in the frontal cortex.
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In addition, lithium decreased the affinity of presynaptic 5-HT3 sites in the hippocampus.
These findings may be also consistent with the inhibitory effect of lithium on presynaptic autoreceptors, which results in an increase of 5-HT release.
It is concluded that enhanced 5-HT neuro transmission which develops during chronic treatment with imipramine or lithium seems to be related to the down-regulation of postsynaptic 5-HT1A receptors in addition to postsynaptic 5-HT2 receptors, which may also have an important role in the antidepressant effects of these drugs.
Chronic but not acute treatment with tri cyclic antidepressants reduced the density of serotonin (5-HT) receptors in rat brain tissues (1, 2) . Most tricyclic antidepressants reduced the 5-HT2 binding sites in cerebral cortical areas, though they had no effect on 5-HT, binding sites except for imipramine (3) . This suggests that the down-regulation of 5-HT2 receptors may be more relevant to anti depressant activity.
Long-term administration of lithium, anti manic-depressive illness drug, also induced a significant reduction of 5-HT, and 5-HT2 sites in the hippocampus (4), but not in the cerebral cortex (5) . Recently, using 3H-5-HT or 3H-8-OH-DPAT (3H-8-hydroxy-2-(di-n propylamino)tetralin) as the ligand, the post synaptic 5-HT, A and 5-HT, B sites could be easily distinguished in the cerebral cortex and hippocampus.
In addition, presynaptic 5-HT3 sites selectively labeled by 3H-8-OH-DPAT were found in the cerebral cortex and striatum (6) .
In the present study, we have extended our previous findings with imipramine and lithium and assessed the effects of chronic adminis tration of both drugs on postsynaptic 5-HT, A, 5-HT,Band presynaptic 5-HT3 sites in the cerebral cortex and hippocampus. Animals were killed by decapitation and their brains rapidly removed at 4°C. The hip pocampus and frontal cortex were dissected out according to the method of Glowinski and Iversen (7) . Crude synaptic membrane frac tions and crude mitochondrial P2 fractions were prepared according to the method described previously (1, 8) . The P2 fractions were dispersed in 10 volumes (vol./wt.) of ice-cold 50 mM Tris-HCI (pH 7.4 at 23°C) by using a Polytron® disrupter (PCU-2) for 10 sec and then incubated at 37 °C for 10 min to remove endogenous 5-HT (9). The pellets were then collected by centrifugation at 48,000 g for 10 min and resuspended in final assay buffer (50 mM Tris-HCI, pH 7.4-8.2) containing 10 iiM nialamide to yield a final concentration of 300-500 ug protein/ml using a Polytron® disrupter for 10 sec. The membranes were stored in liquid nitrogen or kept deep frozen at -80°C until used.
Binding assays
All binding assays were performed by the modified method of Gozlan et al. (6) .
4.1. 3H-5-HT: The measurement of 3H-5 HT binding to 5-HT, (A+B) sites was performed as follows: a 0.8 ml aliquot of membrane suspension in 50 mM Tris-HCI, pH 8.2, containing 1 mM MnCl2 was incubated with 0.1 ml of 3H-5-HT solution (final concen tration of 1-40 nM). Incubation was carried out for 30 min at 23°C, and then the reaction was stopped by the addition of 5 ml of ice cold Tris-HCI buffer. Bound 3H-5-HT was separated from the free ligand by filtration on a Whatman GF/B filter under vacuum, the filter being washed 2 times with 5 ml of the same buffer, and finally, vigorously shaken in scintillation vials containing 5 ml of Univer gel® (Nakarai) for radioactivity counting. Non-specific binding was determined by incubating similar samples with 10 i M 5-HT. The specific binding to 5-HT1 A subsites was obtained by subtracting the non-specific binding, which was defined as the binding in the presence of 0.3 /iM 8-OH-DPAT, from the total 3H-5-HT binding.
The specific binding to 5-HT,B subsites was calculated as follows: the radioactivity bound in the presence of 0.3 aM 8-OH-DPAT minus that persisting in the presence of 10 aM 5-HT.
3H-8-OH-DPAT:
The measurement of 3H-8-OH-DPAT binding to postsynaptic 5
HT1 A sites was performed as follows: a 0.8 ml aliquot of membrane suspension was in cubated for 10 min at 37°C in 50 mM Tris HCI plus 0.1% ascorbate, pH 7.4, containing 0.1 ml of 3H-8-OH-DPAT solution (0.1-50 n M) . The reaction was stopped by the ad dition of 5 ml of ice-cold Tris-HCI buffer. They were then rapidly vacuum-filtered through Whatman GF/B filters and rinsed 2 times with 5 ml of the same buffer. The filters were placed in vials with 5 ml Univer-gel® (Nakarai) scintillation cocktail. The radio activity in the filter was determined by a liquid scintillation spectrometer at an efficiency of 40-50%. Non-specific binding was defined by adding 10 ,aM 5-HT. For the measure ment of 3H-8-OH-DPAT binding to pre synaptic 5-HT3 sites, membranes were sus pended in 0.8 ml of 50 mM Tris-HCI plus 0.1% ascorbate, pH 7.4, containing 1 mM N-ethyl maleimide (NEM) to inactivate postsynaptic sites, and 0.1 ml of 3H-8-OH-DPAT
(1-50 nM) (6). Samples were incubated for 10 min at 37'C. The subsequent procedures were carried out as described for 3H-8-OH-DPAT. Every determination of binding was performed in triplicate. Protein was assayed by the Lowry method (10).
Calculations
Data from the saturation experiments (Scatchard) were evaluated by non-linear computer-assisted curve fitting. Control and treated rats were compared using a two tailed Student's t-test.
Results
The effects of imipramine and lithium on the various classes of 5-HT binding sites, postsynaptic 5-HT1 A and 5-1-11T, B sites and presynaptic 5-HT3 sites, in the frontal cortex and hippocampus are shown in Table 1 (Fig. 2) . In the frontal cortex, there was no effect of lithium on post synaptic 5-HT1 A, 5-HT, B and presynaptic 5 HT3 sites. 
Discussion
We previously reported that the long-term administration of several tricyclic antidepres sants produced a significant decrease in the BmaX value for 5-HT binding sites in rat whole brains (1) . Chronic treatment with imipramine, one of the typical tricyclic antidepressants, was found to reduce the BmaX value for 5-HT, binding sites in the frontal cortex, even though most other tricyclic antidepressants had no effect on 5-HT, sites (3). The present study showed that imipramine decreased the Bmax value for postsynaptic 5-HT, ,, sites as monitored by binding of the radioligand 3H 5-HT or 3H-8-OH-DPAT but did not change the Bmax for postsynaptic 5-HT,,, sites in both the frontal cortex and hippocampus.
The 5 HT, A sites selectively labeled by 3H-8-OH DPAT in the hippocampus (11) (12) (13) (14) are located in the postsynaptic membranes, and they are present in both the post and pre synaptic membranes in the cerebral cortex (15) . Since no reduction of 3H-5-HT or 3H-8 OH-DPAT binding was detected following 5 HT selective degeneration induced by 5,7 dihydroxytryptamine in the cerebral cortex and hippocampus, it can be concluded that the 5-HT autoreceptors controlling the pre synaptic 5-HT release correspond neither to 5-HT, A nor to 5-HT, B sites (16, 17) . It was reported that the 5-HT,,, sites link to ade nylate cyclase in the hippocampus (18, 19) . Therefore, the down-regulation of 5-HT,,, sites induced by the long-term administration of imipramine may result in a decrease in 5 HT stimulated adenylate cyclase activity in the postsynaptic membranes. The relationship between the 5-HT, A sites and the GTP binding protein (Gs and/or GO coupled with adenylate cyclase deserves further inves tigation.
The effects of long-term lithium adminis tration on pre and postsynaptic processes involving 5-HT have been measured in rat hippocampus and cerebral cortex; results indicate that there is an increase of 5-HT release and a reduction of the BmaX value for 5-HT, and/or 5-HT2 in the hippocampus, but not in the cerebral cortex (5, 20) . Our data indicate that chronic administration of lithium to rats decreased the BmaX value for 5-HT, A sites labeled with 3H-5-HT or 3H-8-OH DPAT in the hippocampus, but not in the frontal cortex. From the results that lithium caused the down-regulation of 5-HT, -, sites, lithium as well as imipramine appears to take part in 5-HT stimulated adenylate cyclase activity in the postsynaptic membranes. Since there has been evidence that chronic treat ment with lithium enhances the 5-HT stimu lated adenylate cyclase activity in rat hip pocampus (S. Yamawaki and T. Segawa, unpublished data), the relationship between the down-regulation of 5-HT,, sites and the enhancement of adenylate cyclase requires further investigation.
In the frontal cortex , lithium, unlike imipramine , did not affect the 5-HT,, sites. This difference between lithium and imipramine may explain their different efficacies in manic-depressive illness and in depressive illness.
Experiments with NEM revealed that SH groups play a critical role in 3H-8-OH-DPAT binding to postsynaptic 5-HT,,, sites, but not in binding to presynaptic 5-HT3 sites (21 ) . By this method, the affinity of presynaptic 5 HT3 sites for 3H-8-OH-DPAT was much lower than that of postsynaptic 5-HT,, sites in the cerebral cortex. Our results were similar to those reported by Gozlan et al. (6) . Moreover, contrary to reports of Verge et al. (16, 17) , there have been several papers identifying presynaptic 5-HT autoreceptors as belonging to the 5-HT,,, class (22, 23) . From the present study, it is still not clear whether these presynaptic 5-HT3 sites, which were divided by the treatment with NEM, are the presynaptic terminal autoreceptors controll ing 5-HT release (6, 15) . The present study demonstrated that long-term lithium adminis tration increased the Kd value for presynaptic 5-HT3 sites in the hippocampus, but not in the cerebral cortex. This result suggests that lithium decreases the affinity of presynaptic 5-HT3 sites, which may be possible pre synaptic autoreceptors, and enhances 5-HT release from the presynapse, as was shown in a previous report (4) , consequently inducing the down-regulation of 5-HT, A and 5-HT2 sites in the hippocampal postsynaptic membranes.
